Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD ...

US pharma major Merck & Co is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed bump.

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...